In 2025, darolutamide (brand name Nubeqa) remains a key treatment for certain prostate cancers. This guide breaks down its uses, how it works, and latest updates to help patients understand their options.
What Is Darolutamide?
Darolutamide is an androgen receptor inhibitor—a drug that blocks male hormones (like testosterone) from fueling prostate cancer growth. Unlike similar medications, it has less impact on the brain, which may reduce side effects such as fatigue or dizziness. It also forms an active form, keto-darolutamide, to boost its cancer-fighting effects.
Which Prostate Cancers Does It Treat?
The U.S. Food and Drug Administration (FDA) has approved darolutamide for:
Non-metastatic castration-resistant prostate cancer (nmCRPC): Cancer hasn’t spread but grows despite low testosterone.
Metastatic hormone-sensitive prostate cancer (mHSPC): Cancer has spread but still responds to hormone therapy.
Metastatic castration-sensitive prostate cancer (mCSPC): Advanced cancer sensitive to hormone therapy (recently approved).
Why Clinical Trials Matter
Before approval, darolutamide underwent rigorous clinical trials to test safety and effectiveness. These studies ensure the drug works and is safe for widespread use. Here’s what key trials showed:
ARAMIS Trial (nmCRPC)
- 1,509 men with fast-progressing nmCRPC took darolutamide + hormone therapy or a placebo.
- Results: Darolutamide doubled metastasis-free survival (40.4 months vs. 18.4 months with placebo) and improved overall survival. Side effects (like fatigue) were mild.
ARASENS Trial (mHSPC + Chemotherapy)
- 1,306 men with mHSPC received hormone therapy, chemotherapy (docetaxel), and either darolutamide or placebo.
- Results: Darolutamide reduced death risk by 32.5%. Benefits were consistent across patient groups. Common side effects included low white blood cells but were manageable.
ARANOTE Trial (mCSPC)
- 669 men with mCSPC (not on chemotherapy) took darolutamide or placebo.
- Results: Darolutamide cut progression/death risk by 46%. Most patients on darolutamide showed no disease progression during the study, vs. a median 25 months for placebo.
How Is Darolutamide Taken?
Dosage: 600 mg twice daily (two 300 mg tablets each time), taken with food. Swallow whole—do not crush or chew.
Combination therapy: For mHSPC, it’s often paired with docetaxel (chemotherapy), given via IV every 3 weeks for 6 cycles.
What Side Effects Should I Expect?
Common side effects include:
- Fatigue or tiredness
- Arm/leg pain
- Skin rash
- Elevated liver enzymes (detected via blood tests)
- Low white blood cells (increasing infection risk)
Less common issues: Chest pain, high blood pressure, rare seizures, bone fractures, or infections like pneumonia.
Managing side effects:
- Regular blood tests to monitor liver function and blood counts.
- Rest and light exercise to ease fatigue.
- Calcium, vitamin D, and weight-bearing exercise for bone health.
- Report fever, cough, chest pain, or urinary issues to your doctor right away.
What to Avoid While Taking It
- New medications or supplements without doctor approval (may interact with drugs like topotecan or glyburide).
- Herbal supplements that affect liver enzymes.
- Alcohol and driving until you know how the drug affects you.
Long-Term Outlook
Darolutamide isn’t a cure, but it can slow cancer growth and extend survival. Many patients stay on treatment for months or years with good quality of life. If cancer progresses, your doctor may suggest other options.
Future Research
Scientists are studying darolutamide in combination with immunotherapy or targeted drugs to expand its use—potentially helping more prostate cancer patients, and even those with other cancers tied to male hormones.
Talk to your healthcare team to see if darolutamide is right for you, and to plan your treatment journey.
READ MORE
Prostate Cancer and the PSA Test: Key Facts Every Man Should Know
£168M Fund to Use AI for Early Prostate Cancer Detection
Philips Secures FDA Clearance for New Prostate Cancer Navigation System
